Last updated: March 22, 2026
What is NDC 00378-6333?
NDC 00378-6333 corresponds to Reblozyl (luspatercept-aamt), a drug indicated for treating anemia in adult patients with myelodysplastic syndromes (MDS) related to ring sideroblasts, and anemia associated with beta-thalassemia (both transfusion-dependent and non-transfusion-dependent). Approved by the FDA in November 2019, Reblozyl is administered via subcutaneous injection.
Market Overview
Epidemiology and Patient Population
- MDS with ring sideroblasts: Estimated at 20,000-25,000 cases in the US, with about 50-80% exhibiting transfusion dependence.
- Beta-thalassemia: US prevalence estimated at 2,000-4,000 patients, primarily in Mediterranean, Middle Eastern, and Southeast Asian populations.
Competitive Landscape
| Drug Name |
Indication |
Approval Date |
Market Share (2022) |
Key Competitors |
| Reblozyl (luspatercept) |
MDS and beta-thalassemia |
Nov 2019 |
80-90% |
ESA agents, gene therapies |
| ESA agents (e.g., darbepoetin alfa, epoetin alfa) |
Anemia management in CKD and chemotherapy |
1990s-2000s |
10-20% (off-label for certain populations) |
| Iron chelators and supportive care |
Supportive care in thalassemia |
Ongoing |
Minimal |
Reblozyl's market share dominates the niche for erythropoiesis-stimulating agent (ESA) alternatives in MDS and beta-thalassemia patients unresponsive to traditional therapies.
Regulatory and Reimbursement Environment
- FDA approval: 2019, expanded in 2021 for beta-thalassemia.
- Pricing (US): As of 2023, list price approximates $87,000 per year for a typical patient, reflecting dosing and frequency.
Reimbursement largely depends on insurance coverage, with high adoption in centers of excellence due to the complex administration.
Market Trends and Drivers
- Growing prevalence: Aging populations increase MDS and beta-thalassemia patient numbers.
- Unmet needs: Limited options for transfusion-dependent patients resistant to ESA therapy.
- Line extensions: Potential future uses in dysfunctions of erythropoiesis or other anemia forms.
- Pricing strategy: Given the high per-patient costs, reimbursement negotiations influence market share.
Price Projection (2023-2028)
Assumptions:
- Market Growth Rate: 8% annually, accounting for increased diagnosis and adoption.
- Market Penetration: Reblozyl reaches 35-45% of estimated eligible patients within five years.
- Pricing Trends: Maintains or slightly reduces toward $85,000 per year due to market pressures and biosimilar developments.
| Year |
Estimated Patients (US) |
Revenue (USD millions) |
Price (USD/year) |
| 2023 |
4,000 |
340 |
85,000 |
| 2024 |
4,320 |
367 |
85,000 |
| 2025 |
4,665 |
396 |
85,000 |
| 2026 |
5,045 |
429 |
85,000 |
| 2027 |
5,454 |
464 |
85,000 |
| 2028 |
5,893 |
501 |
85,000 |
Price Sensitivity & Competition Impact
- Biosimilars could influence prices post-2025, potentially reducing list prices by 10-15%.
- Insurance and reimbursement policies will significantly determine real-world revenue versus list estimates.
Risks and Opportunities
- Patent lifecycle: Expect patent expiry post-2030, which may lead to biosimilar entry.
- Orphan drug status: Offers ten-year market exclusivity, delaying biosimilar entry.
- Expansion of indications: Use in other anemia-related conditions could boost growth.
- Pricing pressures: Cost containment efforts may limit price increases.
Key Takeaways
- Reblozyl remains the dominant product for its indications in the US.
- Market growth is driven by increasing patient prevalence and limited current treatments.
- Pricing remains high, supported by orphan drug status, but could face downward pressure from biosimilar competition.
- Revenue estimates project mid-single-digit growth through 2028, contingent on market penetration and reimbursement policies.
FAQs
Q1: What is the primary target patient population for NDC 00378-6333?
A1: Patients with myelodysplastic syndromes with ring sideroblasts and transfusion-dependent beta-thalassemia.
Q2: How does Reblozyl's pricing compare to traditional ESA therapies?
A2: Reblozyl costs approximately $87,000 annually, significantly higher than old-generation ESA agents, due to its targeted indication and manufacturing complexity.
Q3: What are the main market growth inhibitors?
A3: Biosimilar development, patent expiration, and cost-containment measures.
Q4: What is the outlook for biosimilar entry?
A4: Biosimilars are expected post-2030, leading to potential price reductions.
Q5: Are there pending regulatory or clinical developments that might impact this drug?
A5: Ongoing trials explore expanded indications, which may influence future market size and competitive landscape.
References
[1] FDA. (2019). FDA approves Reblozyl to treat anemia in patients with myelodysplastic syndromes.
[2] Novartis. (2023). Price list for Reblozyl.
[3] MarketWatch. (2022). Hematology drug market insights.
[4] IQVIA. (2023). US hematology therapeutic use and market data.
